Has John Stabel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $250 in general payments to John Stabel, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Stabel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Stabel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Stabel, MD

Ophthalmology · Chico, CANPI 1073576328

Payments from drug & device makers

$250in general payments, 2019–2025

Across 9 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Glaukos Corporation$65
Biotissue Holdings Inc.$59
Eyepoint US, Inc.$55
Tarsus Pharmaceuticals, Inc.$38
Dompe US, Inc.$17
Amgen$16

What the payments were for

Food & beverage$250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Glaukos Corporation	2	$65
Biotissue Holdings Inc.	2	$59
Eyepoint US, Inc.	2	$55
Tarsus Pharmaceuticals, Inc.	1	$38
Dompe US, Inc.	1	$17
Amgen	1	$16

How this compares

$250 in reported general payments places this provider in the 20th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California →

Medicare billing

Part B allowed, 2024

$644,226

Medicare patients

1,552

Services billed

4,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XiidraLifitegrast	11	$12,916
RestasisCyclosporine	13	$12,556
LumiganBimatoprost	12	$10,821
Timolol Maleate	169	$4,337
Ketorolac Tromethamine	363	$3,915
Ofloxacin	358	$3,145
Latanoprost	253	$2,956
Prednisolone Acetate	48	$2,124
ValacyclovirValacyclovir Hcl	21	$1,750
Cyclosporine	13	$1,742
ErythromycinErythromycin Base	98	$959
Brimonidine Tartrate	35	$854
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	53	$509
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	17	$200

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Chico

Nisha AcharyaSan Francisco$33M
David WirtaNewport Beach$18.4M
Michael IpPasadena$10.2M
Raymond DouglasBeverly Hills$9.7M
Sherif El HaraziGlendale$9.2M
Daniel SchwartzSan Francisco$8M
Nikolas Londonla Jolla$6.1M
Michael BerlinWest Hollywood$5.7M
Steven JacobsonLos Angeles$4.7M
Peter WinArcadia$4.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →